Navigation Links
Global conference on stem cell therapy for heart disease to be held Jan. 25-27 in NYC
Date:1/23/2012

WHAT: The Seventh International Conference on Cell Therapy for Cardiovascular Disease sponsored by the Cardiovascular Research Foundation (CRF) is a comprehensive program dedicated to the evolving field of cell-based therapies for the repair and regeneration of cardiac and vascular disease, as well as related diseases such as diabetes and stroke. This year's conference will focus on preclinical and clinical studies on the path to commercialization, highlighting the status of molecular, cell, and tissue products in addition to delivery systems.

Noteworthy presentations include a potential role for cell therapy in metabolic syndrome, large-scale studies in patients with heart failure and ST segment elevation myocardial infarction (STEMI) and early phase studies with new biologics involving endometrial cells.

Conference Highlights Include:

  • Periadventitial MAPC Administration in STEMI: Results and Phase II Study
    Thursday, January 26, 2012; 9:00 AM

    Drs. Marc Penn and Warren Sherman will present 1-year results of a Phase 1 clinical trial involving an allogeneic bone marrowderived adherent adult stem cell product in patients with first ST-elevationmyocardial infarction (STEMI). Preliminary 4-month results were recently published in the journal, Circulation Research: http://circres.ahajournals.org/content/110/2/304.full. Investigators will also describe the Phase 2 trial scheduled to begin later this year.

  • SCIPIO: Autologous Cardiac-Derived Stem Cells for LV Dysfunction
    Thursday, January 26, 2012; 1:10 PM

    Dr. Roberto Bolli will present new data on cardiac MRI analyses, as well as, surgical feasibility and safety data from the SCIPIO trial. SCIPIO is a first-in-human, Phase 1, randomized trial of autologous c-kit+ cardiac stem cells (CSCs) in patients with ischemic cardiomyopathy and heart failure. Initial results published in The Lancet showed that intracoronary infusion of autologous CSCs results in a striking improvement in left ventricular ejection fraction, NYHA functional class, quality of life, and in a significant reduction in infarct size.

  • CD34+ Cells for Refractory Angina: ACT 34 CMI Update and Phase 3 Study Design
    Thursday, January 26, 2012; 10:45 AM

    Dr. Timothy Henry will discuss results of the ACT 34 trial, the largest randomized, placebo-controlled, double-blind trial of CD34+ cell therapy for the treatment of patients with class III/IV refractory angina. Dr. Henry will also discuss the study design of a planned Phase III trial set to begin in 2012.

  • SDF-1 for Heart Failure: Results of a Phase I Trial
    Thursday, January 26, 2012; 1:30 PM

    Dr. Marc Penn will present 1-year clinical data results of a plasmid encoding human SDF-1 protein in patients with chronic heart failure. SDF-1 has been identified as a key regulator of stem cell trafficking to sites of cardiac injury and could potentially be used to treat chronic heart failure. Investigators initially found that after four months, patients exhibited clinically significant improvements in quality of life, six-minute walk distance, decreased heart failure symptoms and stabilization of myocardial function.

The latest conference agenda is available at http://celltherapy.crf.org/conference/agenda.html.

WHY: Now in its 11th year of clinical trials, the application of stem cells in the treatment of cardiovascular diseases has seen many notable successes, as well as identified challenges that await the next round of clinical studies. Leaders in the field will convene to present their work, experiences, observations, and opinions on the benefits and unmet challenges of cell-based therapies.

In addition, Friday's sessions will focus on developing a rational policy towards stem cell study and utilization. Leading experts will also explore the benefits and drawbacks of stem cell tourism.

WHO:
Course Director
Warren Sherman, MD
New York-Presbyterian Hospital/Columbia University Medical Center
New York, NY

Course Co-Directors
Josef Bartunek, MD, PhD
Cardiovascular Center, OLV Hospital
Aalst, Belgium

Henricus J. Duckers, MD, PhD
Erasmus University Hospital
Rotterdam, Netherlands

Amit Patel, MD, MS
University of Utah
Salt Lake City, Utah

Marc S. Penn, MD, PhD
Summa Health System
Cleveland, Ohio

WHEN: January 25-27, 2012

WHERE: Vivian and Seymour Milstein Family Heart Center
Myrna L. Daniels Auditorium
NYPH/Columbia University Medical Center
173 Fort Washington Avenue, 1st Floor
New York, NY 10032

For more information visit: http://celltherapy.crf.org/

HOW TO REGISTER: Media may apply for registration by visiting http://celltherapy.crf.org/register/press-registration.html.


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Embedded Mobile & M2M Device revenues to Rise to Almost $19 Billion Globally by 2014, Says Juniper Research
2. International Diabetes Federation awards $2 million to 9 global diabetes research projects
3. Virtual Global Highlights Top Ten Misconceptions about Cloud Computing
4. Global Health Defined as Public Health in a New Lancet Commentary by the Association of Schools of Public Health (ASPH)
5. Dr Yaghouti of Global Laser Vision Receives Patient's Choice Award for 2009
6. Bioniche Achieves Two Additional Milestones Under Licensing Agreement; Endo Takes up Global Rights
7. Now Serving 9 Billion: A Global Town Hall
8. The Global Leaders' Inaugural Meeting a Resounding Success
9. Language Service Leader Expands to Meet Booming, Global Industry Demand.
10. GenomeQuest Hosts Seminar Focused On Web-based Searching for Patent Information Across Global Sequence Databases
11. Global Nutrition Firm Takes Dose of SonicWALL to Boost Network Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... ... is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... OAKLAND, N.J. , June 24, 2016 /PRNewswire/ ... in the design, development and manufacturing of collagen ... and regeneration announced today that Bill Messer ... Sales and Marketing to further leverage the growing ... surgery medical devices. Bill joins the ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
Breaking Medicine Technology: